治疗慢性病毒性肝炎的新途径。

Pathology (Philadelphia, Pa.) Pub Date : 1994-01-01

C C Holland, T L Wright

{"title":"治疗慢性病毒性肝炎的新途径。","authors":"C C Holland, T L Wright","doi":"","DOIUrl":null,"url":null,"abstract":"Despite rapid progress in knowledge of the biology of hepatitis viruses, the ability to treat chronic infection is limited. In fact, interferon-alpha 2b is the only FDA-approved therapy for chronic HBV and chronic HCV. The authors report on the interferons and evolving therapies for chronic viral hepatitis and conclude with a discussion of liver transplantation.","PeriodicalId":79452,"journal":{"name":"Pathology (Philadelphia, Pa.)","volume":"3 1","pages":"23-40"},"PeriodicalIF":0.0000,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New approaches to treatment of chronic viral hepatitis.\",\"authors\":\"C C Holland, T L Wright\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite rapid progress in knowledge of the biology of hepatitis viruses, the ability to treat chronic infection is limited. In fact, interferon-alpha 2b is the only FDA-approved therapy for chronic HBV and chronic HCV. The authors report on the interferons and evolving therapies for chronic viral hepatitis and conclude with a discussion of liver transplantation.\",\"PeriodicalId\":79452,\"journal\":{\"name\":\"Pathology (Philadelphia, Pa.)\",\"volume\":\"3 1\",\"pages\":\"23-40\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology (Philadelphia, Pa.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology (Philadelphia, Pa.)","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

尽管对肝炎病毒生物学的了解进展迅速，但治疗慢性感染的能力是有限的。事实上，干扰素- α 2b是fda批准的唯一治疗慢性HBV和慢性HCV的药物。作者报告干扰素和治疗慢性病毒性肝炎的新方法，最后讨论肝移植。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

New approaches to treatment of chronic viral hepatitis.

Despite rapid progress in knowledge of the biology of hepatitis viruses, the ability to treat chronic infection is limited. In fact, interferon-alpha 2b is the only FDA-approved therapy for chronic HBV and chronic HCV. The authors report on the interferons and evolving therapies for chronic viral hepatitis and conclude with a discussion of liver transplantation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pathology (Philadelphia, Pa.)

自引率

0.00%

发文量